Last updated: February 23, 2026
What is NDC 67877-0493?
NDC 67877-0493 refers to a specific drug product listed in the National Drug Code (NDC) system. To provide accurate analysis, it's crucial to identify the precise drug, dosage, formulation, and manufacturer.
Based on publicly available data, NDC 67877-0493 corresponds to Xenazine (tetrabenazine) 25 mg tablets, produced by Teva Pharmaceuticals. This medication is indicated primarily for the treatment of chorea associated with Huntington's disease.
Market Landscape Overview
Indications and Patient Population
Xenazine treats chorea in Huntington's disease, a rare neurodegenerative disorder impacting an estimated 30,000 Americans[1]. The drug is used in symptomatic management and applies to a niche patient base with a limited treatment window.
Competition
Main competitors include:
- Austedo (deutetrabenazine) by Teva[2]
- Huntington's Disease therapies in experimental phases, such as gene therapies or symptomatic agents like tetrabenazine variants.
Sales Data
Sales figures for tetrabenazine products provide insight:
| Year |
Global Sales (USD Millions) |
Market Share (%) |
Notes |
| 2020 |
150 |
100 |
Exclusively tetrabenazine-based drugs in this niche |
| 2021 |
165 |
+10% |
Slight growth due to increased diagnosis awareness |
| 2022 |
180 |
+9% |
Launch of generic options slightly impacts pricing[3] |
Pricing Benchmarks
- Branded Xenazine typically retails at approximately $9 per 25 mg tablet.
- Generic formulations range from $4 to $6 per tablet, depending on supplier and pharmacy discounts.
Reimbursement and Policy Factors
Medicare and Medicaid cover tetrabenazine with prior authorization. Reimbursement rates hover around $7–$9 per tablet for branded and $3–$5 for generics[4].
Price Projections
Factors Influencing Future Prices:
- Generic Competition: Entry of generic tetrabenazine can reduce prices by roughly 40-50%.
- Demand Stability: The chronic nature of Huntington's disease sustains steady demand.
- Manufacturing Costs: Economies of scale for generics could lower production costs, driving prices downward.
- Regulatory Changes: Price controls or new approvals for alternative therapies could influence market prices.
5-Year Price Outlook
| Year |
Estimated Average Price per 25 mg Tablet (USD) |
Key Drivers |
| 2023 |
$3.50 - $5 |
Continued generic entry, relatively stable demand |
| 2024 |
$3.00 - $4.50 |
Market saturation, price competition increases |
| 2025 |
$2.50 - $4 |
Further generic adoption, potential policy shifts |
| 2026 |
$2 - $3.50 |
Increased generic market share, cost reductions |
| 2027 |
$2 - $3 |
Mature generic market, potential new therapies |
Assumptions:
- No significant regulatory price caps enacted.
- No disruptive innovations on Huntington’s symptom management.
- Continued reimbursement stability.
Strategic Considerations
For manufacturers: Focus on expanding generic availability, optimizing manufacturing efficiency, and engaging in formulary negotiations.
For investors: Monitor generic market entries and policy changes. Price competition predominantly occurs after patents expire, which typically happens 7–10 years post-launch.
Key Takeaways
- NDC 67877-0493 (tetrabenazine 25 mg) has a small but steady market dominated by branded and generic sales.
- The current price of $4–$6 per tablet is likely to decline gradually over the next five years due to generic competition.
- Sales volumes will remain stable due to the limited but chronic patient population.
- Future pricing will heavily depend on regulatory decisions, patent statuses, and the emergence of alternative therapies.
FAQs
1. When do current patents for Xenazine expire?
Patent expiration for branded Xenazine is expected around 2025–2026, opening the market for generics.
2. How will generic entry affect prices?
Generic competition could reduce per-unit prices by 40–50%, with further reductions following increased market penetration.
3. Are there any upcoming regulatory changes that could impact pricing?
Potential policy shifts toward drug price controls or incentives for biosimilars/generics could influence pricing trajectories, primarily post-patent expiry.
4. What are the key challenges for market expansion?
Limited patient population and reimbursement barriers constrain growth. Innovation in alternative treatments could also diminish the role of tetrabenazine.
5. How does demand compare with other symptomatic drugs for neurodegenerative diseases?
Demand remains modest due to disease specificity but consistent because of the chronic management needs in Huntington's disease.
References
- Huntington's Disease Society of America. (2022). Statistics and epidemiology.
- Food and Drug Administration. (2017). Austedo approval details.
- IQVIA. (2022). Pharmaceutical sales and pricing data.
- Centers for Medicare & Medicaid Services. (2022). Reimbursement policies for neurodegenerative disease drugs.
[1] Huntington’s Disease Society of America. (2022). Epidemiology Data.
[2] FDA. (2017). Austedo (deutetrabenazine) approved uses and labels.
[3] IQVIA. (2022). Pharmaceutical Market Reports.
[4] CMS. (2022). Reimbursement guidelines for neurodegenerative treatments.
